As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of BioNTech SE. The largest reported stake is Athos Kg's, at 40.2%. 2 filings are on record since May 14, 2026 (Schedule 13G/A, May 14, 2026).
Sell to companies like BioNTech SE? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
BioNTech SE has 2 Schedule 13D or 13G filings on record since 2026-05-14. 2 holders' latest filing reports 5% or more of ordinary shares, no par value per share (eur1.00 nominal amount) (including ordinary shares represented by american depositary shares). Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 40.2% | 101,702,378 | SCHEDULE 13G/A, 2026-05-14 | 2026-03-31 | |
| 15.8% | 40,076,320 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind BioNTech SE and the warning signs.
Free to see. No signup.
Keep reading
More on BioNTech SE and the records around it.
Companies that share a holder
- ATHOS KG also filed stake reports on 1 other company: Bambusa Therapeutics, Inc. (Nov 2026)
Watch BioNTech SE
Get an email when BioNTech SE files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on BioNTech SE?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on BioNTech SE: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioNTech SE covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Athos Kg | 0 | 101,702,378 | 0 | 101,702,378 | SCHEDULE 13G/A, 2026-05-14 |
| AT Impf GmbH | 0 | 101,702,378 | 0 | 101,702,378 | SCHEDULE 13G/A, 2026-05-14 |
| Thomas Maier | 0 | 101,702,378 | 0 | 101,702,378 | SCHEDULE 13G/A, 2026-05-14 |
| Medine GmbH | 0 | 39,218,111 | 0 | 39,111,390 | SCHEDULE 13G/A, 2026-05-15 |
| Ugur Sahin | 858,209 | 39,218,111 | 858,209 | 39,111,390 | SCHEDULE 13G/A, 2026-05-15 |
The latest filing identifies BioNTech SE by CUSIP 09075V102 and gives its principal executive office as An der Goldgrube 12, Mainz (SCHEDULE 13G/A, 2026-05-15).
What the percentages are based on
See the responses to Item 11 on the attached cover pages, which were calculated based on 252,884,261 ordinary shares of the Issuer outstanding as of March 31, 2026, as reported by the Issuer in its Form 6-K filed with the Securities and Exchange Commission on May 5, 2026.Athos Kg, SCHEDULE 13G/A, 2026-05-14
See the responses to Item 11 on the attached cover pages, which were calculated based on 252,884,261 ordinary shares of the Issuer outstanding as of March 31, 2026.Ugur Sahin, SCHEDULE 13G/A, 2026-05-15
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-05-14 | Athos Kg | 40.2% | SCHEDULE 13G/A |
| 2026-05-15 | Ugur Sahin | 15.8% | SCHEDULE 13G/A |
Questions about who owns BioNTech SE
Who owns BioNTech SE?
On this page, 2 holders' latest ownership filings report 5% or more of BioNTech SE: Athos Kg (40.2%, Schedule 13G/A, filed 2026-05-14) and Ugur Sahin (15.8%, Schedule 13G/A, filed 2026-05-15).
Who are the largest shareholders of BioNTech SE?
By the share each holder's latest filing reports, the largest holders of BioNTech SE on this page are Athos Kg (40.2%) and Ugur Sahin (15.8%).
When did Athos Kg buy into BioNTech SE?
The filings give report dates, not purchase dates. The earliest filing from Athos Kg on this page is the Schedule 13G/A, filed 2026-05-14, reporting 40.2%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for BioNTech SE. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.